Journal ArticleDOI
Pharmacotherapy of Borderline Personality Disorder: Alprazolam, Carbamazepine, Trifluoperazine, and Tranylcypromine
Rex W. Cowdry,David L. Gardner +1 more
TLDR
Patterns of pharmacological response may provide clues to biological mechanisms underlying dysphoria and behavioral dyscontrol in patients with borderline personality disorder.Abstract:
• Sixteen female outpatients with borderline personality disorder and prominent behavioral dyscontrol, but without a current episode of major depression, were studied in a doubleblind, crossover trial of placebo and the following four active medications: alprazolam (average dose, 4.7 mg/d); carbamazepine (average dose, 820 mg/d); trifluoperazine hydrochloride (average dose, 7.8 mg/d); and tranylcypromine sulfate (average dose, 40 mg/d). Each trial was designed to last six weeks. Tranylcypromine and carbamazepine trials had the highest completion rates. Physicians rated patients as significantly improved relative to placebo while receiving tranylcypromine and carbamazepine. Patients rated themselves as significantly improved relative to placebo only while receiving tranylcypromine. Patients who tolerated a full trial of trifluoperazine showed improvement, those receiving carbamazepine demonstrated a marked decrease in the severity of behavioral dyscontrol, and those receiving alprazolam had an increase in the severity of the episodes of serious dyscontrol. As an adjunct to psychotherapy, pharmacotherapy can produce modest but clinically important improvement in the mood and behavior of patients with borderline personality disorder. As a research tool, patterns of pharmacological response may provide clues to biological mechanisms underlying dysphoria and behavioral dyscontrol.read more
Citations
More filters
Journal ArticleDOI
Cognitive-Behavioral Treatment of Chronically Parasuicidal Borderline Patients
TL;DR: Subjects who received dialectical behavior therapy had fewer incidences of parasuicide and less medically severe parasuicides, were more likely to stay in individual therapy, and had fewer inpatient psychiatric days.
Journal ArticleDOI
Dialectical Behavior Therapy for Patients with Borderline Personality Disorder and Drug-Dependence
Marsha M. Linehan,Henry Schmidt Iii,Linda A. Dimeff,J. Christopher Craft,Jonathan W. Kanter,Katherine Anne Comtois +5 more
TL;DR: Dialectical Behavior Therapy has been shown to be more effective than treatment-as-usual in treating drug abuse in this study, providing more support for DBT as an effective treatment for severely dysfunctional BPD patients across a range of presenting problems.
Journal ArticleDOI
What Is a “Mood Stabilizer”? An Evidence-Based Response
Mark S. Bauer,Landis Mitchner +1 more
TL;DR: The evidence supported a role for lithium as first-line agent for treatment of bipolar disorder when all four treatment roles are considered and highlights unmet needs and promising agents and provides a yardstick for evaluating new treatment strategies.
Journal ArticleDOI
Fluoxetine and Impulsive Aggressive Behavior in Personality-Disordered Subjects
TL;DR: Fluoxetine treatment has an antiaggressive effect on impulsive aggressive individuals with DSM-III-R personality disorder.
References
More filters
Journal ArticleDOI
Crossing the border into borderline personality and borderline schizophrenia. The development of criteria.
TL;DR: Two item sets were developed to provide diagnostic criteria for the two concepts Borderline Schizophrenia and Borderline Personality, which will be used in the forthcoming DSM-III classification for the categories of Borderline personality Disorder and Schizotypal Personality Disorder.
Journal ArticleDOI
The diagnostic interview for borderline patients.
TL;DR: The content, administration, reliability, construct validity, and training requirements for a semistructured diagnostic interview for borderline patients show that the interview provides a reasonably constructed and reliable method for researchers and clinicians interested in identifying the syndrome of borderline personality disorders.
Journal ArticleDOI
Subaffective disorders: dysthymic, cyclothymic and bipolar II disorders in the "borderline" realm.
TL;DR: Different forms of subaffective disorders are described to illustrate the significant overlap between these disorders and borderline characterologic psychopathology.
Journal ArticleDOI
Carbamazepine in manic-depressive illness: a new treatment.
TL;DR: In this paper, the authors evaluated carbamazepine (Tegretol), a drug of choice for treatment of temporal lobe epilepsy, in a double-blind placebo-controlled trial in patients with manic-depressive illness.
Journal ArticleDOI
The Validity of DSM-III Borderline Personality Disorder: A Phenomenologic, Family History, Treatment Response, and Long-term Follow-up Study
TL;DR: To test the validity of the DSM-III diagnosis of borderline personality disorder (BPD), the phenomenology, family history, treatment response, and four-to-seven-year long-term outcome of a cohort of 33 patients meeting DSM- III criteria for BPD are examined.